• Find people
• Intranet

Applied clinical research in hematological malignances Beatriz Bellosillo

Publications 2025 (10)

• Lagrave J, Domingo L^*, Barceló-Vidal J, Comas M, Jiménez C, Ferrández O, Castells X, Sala M. Association between oral anticoagulant therapy and in-hospital complications and mortality. Br J Clin Pharmacol 2025: (en Premsa).
  Cites:0
  Cites:0
• Rocha P^*, Bach R, Masfarre-Pinto L, Hernandez S, Navarro-Gorro N, Rossell A, Villanueva X, Giner M, Sánchez I, Galindo M, del Rey-Vergara R, Iñañez A, Sánchez-Espiridión B, Lu W, Acedo A, Berenguer-Molins P, Sánchez-Font A, Chalela R, Curull V, Taus A, Hardy-Werbin M, Sausen M, Georgiadis A, White J, Jackson JB, Moliner L, Clavé S, Bellosillo B, Rovira A, Wistuba I, Solis-Soto L, Perera J, Arriola E. Molecular and immunological features associated with long-term benefits in metastatic NSCLC patients undergoing immune checkpoint blockade. OncoImmunology 2025; 14(1): 2469377.
  Cites:0
  Cites:0
• Vinaixa J, Martínez-Bosch N, Gibert J, Manero-Rupérez N, Santofimia-Castaño P, Baudou FG, Vera RE, Pease DR, Iglesias M, Sen S, Wang X, Almada LL, Marks DL, Moreno M, Iovanna JL, Rabinovich GA^*, Fernández-Zapico ME^*, Navarro P^*. Nuclear Galectin-1 promotes KRAS-dependent activation of pancreatic cancer stellate cells. Proc. Natl. Acad. Sci. U. S. A. 2025; 122(14): e2424051122.
  Cites:1
  Cites:1
• Verdu-Bou M, Baptista MJ, Ribeiro ML, Méndez-López A, Profitos-Peleja N, Frontzek F, Roué G, Mate JL, Pellicer M, Abrisqueta-Costa P, Castellví J, Bastos-Oreiro M, Menárguez J, Alcoceba M, González-Barca E, Climent F, Salar A, Sancho JM, Staiger AM, Ott G, Anagnostopoulos I, Esteller M, Lenz G, Tapia G, Navarro JT^*. The role of miR-150-5p/E2F3/survivin axis in the pathogenesis of plasmablastic lymphoma and its therapeutic potential. Blood Adv 2025; 9(12): 2953-2967.
  Cites:1
  Cites:1
• Papaleo NF, Molina-Alvarez A, Tapia G, Onieva R, Salido M, Lome-Maldonado C, Ara-Mancebo X, Puiggros A, Espinet B, Blazquez C, Fuertes D, Sánchez-González B, Yelamos J, Calvo X, Colomo L^*. Combined immunohistochemical profile CD10/LMO2/MYC is a useful tool to screen MYC rearrangements in aggressive large B-cell lymphomas. Virchows Arch 2025; 486(5): 951-959.
  Cites:0
  Cites:0
• Osuna-Gómez R, Zamora C, Novelli S, Garcia-Pallarols F, Rodriguez Y, Domingo A, Canet M, Olivera P, Mulet M, Cantó E, Valcarcel D, Sánchez-González B, Vidal S^*. Interplay of leucocyte-platelet complexes and clinical response to eltrombopag in immune thrombocytopenia patients. Br J Haematol 2025; 206(4): 1200-1212.
  Cites:2
  Cites:2
• Martelli V, Vidal J, Salvans S, Fernández Rodríguez C, Badia J, Linares JL, Jimenez M, Sibilio A, Gibert J, Pérez M, Bellosillo B, Calon A, Pietrantonio F, Iglesias M, Pascual M, Montagut C^*. Liquid Biopsy in Peritoneal Carcinomatosis from Colorectal Cancer: Current Evidence and Future Perspectives. Cancers 2025; 17(9): 1461.
  Cites:0
  Cites:0
• Pérez-Lamas L, Segura-Díaz A, García-Delgado R, Álvarez-Larran A, Senín MA, Mora-Casterá E, Fox ML, Pastor-Galán I, Azaceta G, Garrido-Paniagua S, Perez-Lopez R, Trejos-Carvajal DM, Angona A, Albo-López C, Lorente-Alegre P, Vara M, Vera-Goñi JA, De Miguel-Llorente D, Fernández-Rodríguez A, Marin-Sanchez A, Hernando-Megido A, Gómez-Casares MT, Stuckey R, Carreño-Tarragona G, De Las Heras Rodríguez N, Xicoy B, Pérez-Encinas M, Mata-Serna R, Núñez Martin-Buitrago L, Ferrer-Marín F, Amer-Salas N, Guillén-Rienda C, Vélez P, Lamarca-Eraso L, Martin S, Luts-Khoroz I, De Cabo-López E, Gil A, Martín-Consuegra Ramos S, Marco-de Lucas F, Otero Martinez-Fornes MJ, Martin Mateos ML, Arquero T, Cabezudo-Pérez E, López-Gómez LA, Martínez-Hellin A, Tejedor A, Herrera de Pablo E, Mata-Vazquez MI, Castillo-Valero I, Fernández MJ, Aguilar C, Santaliestra M, García-Menchon A, Navas B, Duran MA, Pérez-Sala M, Hernández-Santamaría T, Muñoz-Jarreño MA, Dávila-Valls J, Torres-Jiménez W, Gonzálvez-Fernández JA, Torres-Mantilla HA, Cobo-Rodríguez T, Abuin A, Perez F, Osorio-Prendes S, Beneit-Villena P, Peralta R, Herrera F, Cañamero-Giro E, Jiménez-Bárcenas R, Gasior M, De Villambrosía S, Tercero-Mora Rodriguez MT, Menéndez-Cuevas M, Ruiz BC, Fonseca-Santos M, Garcés-Piquer S, De La Puerta R, Lorenzo-Vizcaya Á, Hernández-Boluda JC^*, García-Gutiérrez V^*. Real world outcomes of momelotinib in myelofibrosis patients with anemia: results from the MOMGEMFIN study. Blood Cancer J 2025; 15(1): 67.
  Cites:2
  Cites:2
• Oñate G, Garrido A, Arnan M, Pomares H, Alonso E, Tormo M, Diaz-Beya M, Vives S, Zamora L, Sampol A, Coll R, Salamero O, Cervera M, Garcia A, Vall-Llovera F, Garcia-Avila S, Bargay J, Ortin X, Iranzo E, Guijarro F, Pratcorona M, Nomdedeu JF, Esteve J, Sierra J^*. Diverse real-life outcomes after intensive risk-adapted therapy for 1034 AML patients from the CETLAM Group. Blood Cancer J 2025; 15(1): 4.
  Cites:0
  Cites:0
• Pavlova S, Malcikova J, Radova L, Bonfiglio S, Cowland JB, Brieghel C, Andersen MK, Karypidou M, Biderman B, Doubek M, Lazarian G, Rapado I, Vynck M, Porret NA, Andres M, Rosenberg D, Sahar D, Martínez-Laperche C, Buño I, Hindley A, Donaldson D, Sánchez JB, García-Marco JA, Serrano-Alcalá A, Ferrer-Lores B, Fernández-Rodríguez MC, Bellosillo B, Stilgenbauer S, Tausch E, Nikdin H, Quinn F, Atkinson E, Van de Corput L, Yildiz C, Bilbao-Sieyro C, Florido Y, Thiede C, Schuster C, Stoj A, Czekalska S, Chatzidimitriou A, Laidou S, Bidet A, Dussiau C, Nollet F, Piras G, Monne M, Smirnova S, Nikitin E, Sloma I, Claudel A, Largeaud L, Ysebaert L, Valk PJM, Christian A, Walewska R, Oscier D, Sebastião M, da Silva MG, Galieni P, Angelini M, Rossi D, Spina V, Matos S, Martins V, Stoklosa T, Pepek M, Baliakas P, Andreu R, Luna I, Kahre T, Murumets Ü, Pikousova T, Kurucova T, Laird S, Ward D, Alcoceba M, Balanzategui A, Scarfo L, Gandini F, Zapparoli E, Blanco A, Abrisqueta-Costa P, Rodríguez-Vicente AE, Benito R, Bravetti C, Davi F, Gameiro P, Martínez-López J, Tazón-Vega B, Baran-Marszak F, Davis Z, Catherwood M, Sudarikov A, Rosenquist R, Niemann CU, Stamatopoulos K, Ghia P, Pospisilova S^*. Detection of clinically relevant variants in the TP53 gene below 10% allelic frequency: A multicenter study by ERIC, the European Research Initiative on CLL. Hemasphere . 2025; 9(1): e70065 (Acceptat).
  Cites:0
  Cites:0